Hypertension, diabetes, cognitive impairment, renal cancer, polymyalgia rheumatica and chronic hemodialysis treatment: so many diseases or just only one?

2019 ◽  
Author(s):  
Marta Węgrzyn-Bęk ◽  
Dorota Boniek-Poprawa ◽  
Krzysztof Marczewski
Keyword(s):  
Cognitive Impairment ◽  
Renal Cancer ◽  
Polymyalgia Rheumatica ◽  
Chronic Hemodialysis ◽  
Hemodialysis Treatment

Brain MRI findings and cognitive impairment in patients undergoing chronic hemodialysis treatment

1995 ◽  
Vol 134 (1-2) ◽  
pp. 83-88 ◽  
Author(s):  
Gudrun Fazekas ◽  
Franz Fazekas ◽  
Reinhold Schmidt ◽  
Peter Kapeller ◽  
Hans Offenbacher ◽  
...  
Keyword(s):  
Cognitive Impairment ◽  
Brain Mri ◽  
Chronic Hemodialysis ◽  
Mri Findings ◽  
Hemodialysis Treatment

scholarly journals Cefazolin serum concentrations with fixed intravenous dosing in patients on chronic hemodialysis treatment

1999 ◽  
Vol 14 (8) ◽  
pp. 2050-2051 ◽  
Author(s):  
D. Kuypers ◽  
J. Vanwalleghem ◽  
B. Maes ◽  
T. Messiaen ◽  
Y. Vanrenterghem ◽  
...  
Keyword(s):  
Chronic Hemodialysis ◽  
Serum Concentrations ◽  
Hemodialysis Treatment

scholarly journals Immunological Effects of a Single Hemodialysis Treatment

Medicina ◽  
2020 ◽  
Vol 56 (2) ◽  
pp. 71 ◽  
Author(s):  
Andrea Angeletti ◽  
Fulvia Zappulo ◽  
Chiara Donadei ◽  
Maria Cappuccilli ◽  
Giulia Di Certo ◽  
...  
Keyword(s):  
Adaptive Response ◽  
Chronic Hemodialysis ◽  
Hemodialysis Treatment ◽  
Immune Balance ◽  
Immunological Effects ◽  
Exogenous Factors ◽  
Immune System Modulation ◽  
Stage Renal Disease ◽  
End Stage ◽  
Innovative Techniques

Immune disorders, involving both innate and adaptive response, are common in patients with end-stage renal disease under chronic hemodialysis. Endogenous and exogenous factors, such as uremic toxins and the extracorporeal treatment itself, alter the immune balance, leading to chronic inflammation and higher risk of cardiovascular events. Several studies have previously described the immune effects of chronic hemodialysis and the possibility to modulate inflammation through more biocompatible dialyzers and innovative techniques. On the other hand, very limited data are available on the possible immunological effects of a single hemodialysis treatment. In spite of the lacking information about the immunological reactivity related to a single session, there is evidence to indicate that mediators of innate and adaptive response, above all complement cascade and T cells, are implicated in immune system modulation during hemodialysis treatment. Expanding our understanding of these modulations represents a necessary basis to develop pro-tolerogenic strategies in specific conditions, like hemodialysis in septic patients or the last session prior to kidney transplant in candidates for receiving a graft.

Personality disorders as a result of symptom of chemotherapy-related cognitive impairment (CRCI) antiangiogenic treatment for metastatic renal cancer: A case report of 71-year-old women.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e13560-e13560 ◽  
Author(s):  
Ewa Wachula ◽  
Jolanta Zok ◽  
Marzenna Ziomek ◽  
Piotr Jan Wysocki ◽  
Wojciech Rogowski
Keyword(s):  
Cognitive Impairment ◽  
Personality Disorders ◽  
Renal Cancer ◽  
Verbal Memory ◽  
Psychiatric Symptoms ◽  
Social Withdrawal ◽  
Hematological Toxicity ◽  
Metastatic Renal Cancer ◽  
Cognitive Changes ◽  
Angiogenic Therapy

e13560 Background: Chemotherapy-related cognitive impairment, known also as chemo brain, is defined as cognitive changes experienced by patients undergoing chemotherapy, especially in aspects of visual and verbal memory, attention and psychomotor functions. Cognitive changes and dysfunction after common cancer chemotherapy and recently appearing after biologic agents are increasing as a disturbing side-effect in cancer survivors. The etiology of this phenomenon is not well understood. Methods: We present the case of 71-year- old female, with metastatic renal cancer who are exposed to anti-angiogenic treatment for years.From 2005 to 2009 the patient was treated by combination therapy which consisted of bevacizumab and INF-alfa.The anti-angiogenic therapy was discontinued prematurely because of cardiac toxicity. Partial response of metastatic lesions was achieved as a result of the treatment. In 2010, new metastases were found, and a second line therapy by m-TOR inhibitor everolimus was commenced. Because of hematological toxicity of CTC grade 3, the patient required a 50% dose reduction. During anti-angiogenic treatment some psychiatric symptoms such as paranoid personality disorders, memory impairment, dementia, emotional coldness and social withdrawal were observed. Results: In laboratory tests any electrolytes and metabolic imbalance were noticed. The CT and the MR imaging of the head excluded any structural damages and focal brain parenchymal lesions. Psychotherapy and pharmacotherapy were suggested.The patient is still on everolimus until now in order to maintain stabilization. Conclusions: The chemotherapy-related cognitive impairment can be problematic for survivors. Better understanding factors that contribute to chemotherapy-related cognitive dysfunction is important because this information could identify patients at risk and inform treatment.

Bone Marrow Amyloidosis with Erythropoietin-resistant Anemia in a Patient Undergoing Chronic Hemodialysis Treatment

2003 ◽  
Vol 96 (5) ◽  
pp. 491-493
Author(s):  
Ramazan Çetinkaya ◽  
Ali Riza Odabas ◽  
Yilmaz Selcuk ◽  
Zekai Erman ◽  
Hasan Kaya
Keyword(s):  
Bone Marrow ◽  
Chronic Hemodialysis ◽  
Hemodialysis Treatment

The Effect of Type and Vascular Access Quality on the Outcome of Chronic Hemodialysis Treatment

2010 ◽  
Vol 20 (5) ◽  
pp. S118-S121 ◽  
Author(s):  
Krzysztof Letachowicz ◽  
Wacław Weyde ◽  
Waldemar Letachowicz ◽  
Marian Klinger
Keyword(s):  
Vascular Access ◽  
Chronic Hemodialysis ◽  
Hemodialysis Treatment

OP1-08 HIGH PREOPERATIVE C-REACTIVE PROTEIN VALUES PREDICT POOR SURVIVAL IN PATIENTS ON CHRONIC HEMODIALYSIS UNDERGOING NEPHRECTOMY FOR RENAL CANCER

2014 ◽  
Vol 191 (4S) ◽  
Author(s):  
Kenji Omae ◽  
Tsunenori Kondo ◽  
Kazuhiko Yoshida ◽  
Toshio Takagi ◽  
Hirohito Kobayashi ◽  
...  
Keyword(s):  
Renal Cancer ◽  
Chronic Hemodialysis ◽  
C Reactive Protein ◽  
Poor Survival ◽  
Reactive Protein

Biokompatibilitätsprobleme bei der Hämodialyse

1990 ◽  
Vol 10 (02) ◽  
pp. 84-91 ◽  
Author(s):  
U. Weber ◽  
J. Lissmann ◽  
R. Bambauer
Keyword(s):  
Side Effects ◽  
Chronic Hemodialysis ◽  
Low Risk ◽  
Dialysis Fluid ◽  
Hemodialysis Treatment ◽  
Number Of Patients ◽  
Artificial Surfaces ◽  
Near Future

ZusammenfassungSeit erstmals Interaktionen von Blut und körperfremden Materialien bei der chronischen Hämodialysebehandlung beobachtet wurden, folgten zahlreiche Untersuchungen, um das Phänomen der Biokompatibilität zu ergründen. Dies hatte zur Folge, daß erhebliche Verbesserungen bei den Membranen, Schlauchsystemen, Geräten und der Behandlung selbst erzielt werden konnten. Im folgenden wird versucht, einen Überblick über die auslösenden Ursachen und die Phänomene, die durch die Interaktion von Blut mit körperfremden Oberflächen verursacht werden, aufzuzeigen.Die Probleme, die bei der Entwicklung biokompatibler Membranen vorhanden sind, scheinen in naher Zukunft noch nicht alle lösbar zu sein. Unsere ganze Sorgfalt muß daher der Hämodialysebehandlung selbst und der Verringerung ihrer möglichen Nebenwirkungen, die z.B. durch Reste von Sterilisationsmitteln, endotoxinhaltige Dialysierflüssigkeiten hervorgerufen werden können, gelten. Besonders im Hinblick darauf, daß die Zahl der Patienten, die Biomaterialien benötigen, rasch zunimmt und diese Patienten länger leben, wodurch sie den Gefahren durch die Biounverträglichkeit der Materialien länger ausgesetzt werden, sind wir alle aufgefordert, unseren Patienten eine risikoarme Hämodialyse zu ermöglichen served in the treatment of chronic hemodialysis, numerous investigations were performed to definite the phenomena of biocompatibility. As a consequence, considerable improvements in membranes, tube systems, equipments and in the treatment itself have been accomplished. The following is an attempt to demonstrate the initiating causes and the phenomena which results from the interaction of blood with artificial surfaces.The problems being encountered in the development of biocompatible membranes are not likely to all be solved in the near future. We must, therefore, concentrate all our efforts on the hemodialysis treatment itself and on the reduction of its possible side-effects which can, for example, be caused by the remnants of sterilizing agents, dialysis fluid containing endotoxin, etc. Especially in view of the fact that the number of patients requiring biomaterials is rapidly increasing and that these patients are living longer, whereby they are exposed to the dangers of bioincompatibility of the materials for a longer period of time, we are all called upon to provide low-risk hemodialysis for our patients.

Lp(a) and premature mortality during chronic hemodialysis treatment

1994 ◽  
Vol 67-68 ◽  
pp. 419-427 ◽  
Author(s):  
Michael D. Cressman ◽  
Daniel Abood ◽  
June O'Neil ◽  
Henry F. Hoff
Keyword(s):  
Premature Mortality ◽  
Chronic Hemodialysis ◽  
Hemodialysis Treatment
Sign in / Sign up

Export Citation Format

Share Document